AZN GB0009895292

Report

Delayed London Stock Exchange - 06/21 11:37:35 am
8408	GBX		+0.29%

02:38p

Dual-antibody drugs effective against COVID-19 variants in animal study

10:43a

Bionity - Mix-and-match vaccines generate a particularly strong immune response

07:45a

ASTRAZENECA : GSK to boost spending power of pharma business post break-up

Calendar

Upcoming events on ASTRAZENECA PLC

06/23/21		Guggenheim Biopharma Next Decade Conference
07/02/21		UBS Bus Tour
07/29/21		Interim 2021 Earnings Release
11/12/21		Q3 2021 Earnings Release

Past events on ASTRAZENECA PLC

06/18/21		J.P. Morgan European Healthcare Conference
06/14/21		Bank of America Securities Napa Biopharma Virtual Conference
06/10/21		Wolfe Pipelines Unplugged Meeting
06/09/21		Goldman Sachs Global Healthcare conference

Upcoming sector events for ASTRAZENECA PLC

06/21/21 \| 08:00am		ROCHE HOLDING AG : European Academy of Neurology Meeting - EPO323
06/21/21 \| 10:45am		ROCHE HOLDING AG : European Academy of Neurology Meeting - OS3003
06/21/21 \| 10:45am		ROCHE HOLDING AG : European Academy of Neurology Meeting - Satralizumab in patients with neuromyelitis optica spectrum
06/21/21 \| 11:00am		ROCHE HOLDING AG : European Academy of Neurology Meeting - OS3005

More events

Past sector events for ASTRAZENECA PLC

06/20/21 \| 01:30pm		ROCHE HOLDING AG : European Academy of Neurology Meeting - EPO216
06/20/21 \| 01:30pm		ROCHE HOLDING AG : European Academy of Neurology Meeting - Claims-based algorithm to identify NMOSD patients and relaps
06/20/21 \| 09:00am		ROCHE HOLDING AG : European Academy of Neurology Meeting - OS2010
06/20/21 \| 09:00am		ROCHE HOLDING AG : EUROPEAN ACADEMY OF NEUROLOGY MEETING - PHASE II PASADENA PART 1 WEEK 52 RESULTS: Evaluating safety

Annual publications

Annual results		2016	2017	2018	2019	2020	2021 (e)
Sales M $	Released Forecast Spread	23 002 23 116 -0,49%	22 465 22 117 1,6%	22 090 22 157 -0,30%	24 384 24 440 -0,23%	26 617 26 378 0,91%	30 966
Operating income (EBITDA) M $	Released Forecast Spread	7 259 6 503 12%	6 713 6 604 1,7%	7 140 6 767 5,5%	6 686 6 882 -2,8%	8 311 8 087 2,8%	9 951
Operating profit (EBIT) M $	Released Forecast Spread	6 721 6 648 1,1%	6 855 6 450 6,3%	5 672 5 897 -3,8%	6 436 6 631 -2,9%	7 340 7 417 -1,0%	8 897
Pre-Tax Profit (EBT) M $	Released Forecast Spread	3 552 2 340 52%	2 227 2 602 -14%	1 993 2 712 -27%	1 548 2 081 -26%	3 916 4 387 -11%	5 218
Net income M $	Released Forecast Spread	3 499 2 413 45%	3 001 2 477 21%	2 155 2 306 -6,6%	1 335 1 895 -30%	3 196 2 930 9,1%	4 588
EPS $	Released Forecast Spread	2,76 1,92 44%	2,37 1,90 25%	1,70 1,79 -4,8%	1,03 1,41 -27%	2,44 2,50 -2,3%	3,20
Announcement Date		02/02/2017	02/02/2018	02/14/2019	02/14/2020	02/11/2021

Quarterly publications

Previous period

Next period

Quarterly results		2017 S1	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2 (e)	2021 Q3 (e)	2021 Q4 (e)	2022 Q1 (e)	2022 Q2 (e)
Sales M $	Released Forecast Spread	10 456 10 440 0,15%	6 417 6 332 1,3%	5 491 5 398 1,7%	5 823 5 571 4,5%	6 406 6 056 5,8%	6 664 6 749 -1,3%	6 354 5 948 6,8%	6 275 6 279 -0,07%	6 578 6 642 -0,96%	7 410 7 104 4,3%	7 320 6 997 4,6%	7 438	7 936	8 669	7 951	7 716
Operating income (EBITDA) M $	Released Forecast Spread		2 739 3 280 -16%	1 773 1 529 16%	1 220 1 568 -22%	1 473 1 909 -23%	2 220 1 865 19%	2 061	1 994	1 972 2 335 -16%	2 284 1 737 31%	2 692 2 904 -7,3%	2 148	2 641	2 550
Operating profit (EBIT) M $	Released Forecast Spread	3 215 2 650 21%	2 192 2 422 -9,5%	1 650 1 552 6,3%	1 361 1 125 21%	1 880 1 763 6,6%	1 545 1 746 -11%	1 854 1 688 9,9%	1 792 1 679 6,7%	1 795 1 811 -0,86%	1 899 1 962 -3,2%	2 524 2 545 -0,81%	1 852	2 151	2 326
Pre-Tax Profit (EBT) M $	Released Forecast Spread		730 1 516 -52%	758 849 -11%	141 281 -50%	409 841 -51%	240 486 -51%	935 896 4,4%	961 761 26%	853 904 -5,6%	1 167 1 033 13%	1 608 1 591 1,1%
Net income M $	Released Forecast Spread		1 034 1 212 -15%	593 596 -0,55%	130 268 -51%	299 651 -54%	313 771 -59%	780 698 12%	756 630 20%	648 753 -14%	1 012 881 15%	1 561 1 347 16%	651	973	1 420
EPS $	Released Forecast Spread		0,82 0,86 -4,5%	0,47 0,49 -3,9%	0,10 0,21 -53%	0,23 0,49 -53%	0,24 0,34 -30%	0,59 0,50 19%	0,58 0,48 21%	0,49 0,56 -13%	0,78 0,67 16%	1,19 1,02 17%	0,57	0,70	0,80
Announcement Date		07/27/2017	02/14/2019	04/26/2019	07/25/2019	10/24/2019	02/14/2020	04/29/2020	07/30/2020	11/05/2020	02/11/2021	04/30/2021

Analysis

AstraZeneca : JPMorgan, Goldman Sachs delay workers' return to U.K. offices